On March 25, 2020, a consortium of life science companies with the Bill & Melinda Gates Foundation announced a collaboration to promote the development, manufacture, and delivery of diagnostics and treatments to combat COVID-19.
With extensive years of expertise in the healthcare sector and the pharmaceutical research, these expert companies will raise financial aid and the resources required to find a prompt solution to this virus, which is having a global impact, mainly evident in healthcare systems around the world.
“We look to harness that knowledge and experience -combining it where possible- to connect with national regulators and the World Health Organization to see if we can help flatten the curve of this epidemic and make sure the results reach everyone around the world, particularly those at highest risk,” said Mark Suzman, CEO of the Bill & Melinda Gates Foundation.
It is good news for the global health at this critical time where the collaboration will generate the strength required to defeat COVID-19 pandemic.
Companies participating in this initiative are: BD, bioMérieux, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck (known as MSD outside the U.S. and Canada), Merck KGaA, Novartis, Pfizer and Sanofi.
For further news, visit: https://gates.ly/39xD96T
We also invite you to visit our Coronavirus page and learn what each Latin American country and industry is doing: https://fifarma.org/es/coronavirus